Publish Time: 2022-04-28 Origin: Site
Tirzepatide intermediates a novel investigational glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist that integrates the actions of two glucagon hormones into a single molecule and represents a new class of drugs being investigated for the treatment of type 2 diabetes. Next, we take a look at the profile and suppliers of biology long acting phase 2. Here are some answers.
Here is the content list:
l Tirzepatide intermediates are more effective than glargine insulin in terms of A1C and weight loss in adults with type 2 diabetes.
l The supplier of Tirzepatide intermediates was selected as Chengdu Pukang Biotechnology Co.
Tirzepatide intermediates are more effective than glargine insulin in terms of A1C and weight loss in adults with type 2 diabetes.
Newly published data show that participants maintained A1C and weight control for up to two years in SURPASS-4, the largest and longest SURPASS trial completed to date. no increased cardiovascular risk was observed for energy metabolism fda approved phase 3; a risk ratio of 0.74 was observed for MACE-4 events. SURPASS-4 is SURPASS-4 is the largest and longest clinical trial completed to date, which investigated tripeptide as a potential treatment for type 2 diabetes. The primary endpoint was measured at 52 weeks and participants continued treatment for up to 104 weeks or until study completion. Completion of the study was triggered by the occurrence of a major adverse cardiovascular event (MACE) to assess CV risk. In newly published data from the post-52-week treatment period, participants taking Tirzepatide intermediates maintained A1C and weight control for up to two years. The overall safety of Tirzepatide intermediates assessed throughout the study period was consistent with the safety results measured at week 52, with no new findings up to week 104. Gastrointestinal side effects were the most commonly reported adverse events, usually occurring during escalation and then decreasing over time.
The supplier of Tirzepatide intermediates was selected as Chengdu Pukang Biotechnology Co.
Chengdu Pukang Biotechnology Co., Ltd was established in 2008 and is located in the National Cross-Strait Technology Industrial Development Park - Cross-Strait Technology Park in Wenjiang District, Chengdu, focusing on the long-term development of peptide drugs for chronic diseases. As a manufacturer, it integrates the production, sales, and R&D of chemical synthesized powder lab high purity solution. At present, our company has an R&D center of 2,400 square meters and a production workshop of 1,000 square meters. We plan to build a 12,000 sqm production base with quality system management according to GMP standards. In recent years, Pukang has been audited more than ten times by well-known pharmaceutical companies at home and abroad and has been recognized. Our main product is Tirzepatide intermediates and we are cooperating with innovative pharmaceutical companies to build a research and development platform for Tirzepatide intermediates. Our company is committed to providing the best products and services to our customers worldwide under the philosophy of "Quality First, Technology First".
We are committed to bringing more and better products to our customers, which is what we have been doing. If you are interested in our Tirzepatide intermediates products or have other needs, please feel free to contact us. Our official website is https://www.pu-kang.com/, we welcome you and look forward to working with you. Our cost-effective products will bring you a better experience of using them.